Verve Therapeutics Cash Over Time
| VERV Stock | USD 4.60 0.05 1.10% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Verve Therapeutics Performance and Verve Therapeutics Correlation. Verve |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 0.303 | Quarterly Revenue Growth 1.202 | Return On Assets (0.22) | Return On Equity (0.41) |
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash Analysis
Compare Verve Therapeutics and related stocks such as Adaptive Biotechnologies, Beam Therapeutics, and Caribou Biosciences Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADPT | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 55 M | 96.6 M | 123.4 M | 139.1 M | 90 M | 65.1 M | 102.9 M |
| BEAM | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 146.4 M | 37.2 M | 162.2 M | 965.6 M | 232.8 M | 435.9 M | 311.5 M |
| CRBU | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 16 M | 240.4 M | 58.3 M | 51.2 M | 89.5 M |
| SANA | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 80 M | 412 M | 253 M | 176.8 M | 133.5 M | 199.1 M |
| NTLA | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 75.8 M | 273.1 M | 340.7 M | 58.9 M | 57.2 M | 160 M | 123.4 M | 523.5 M | 226.7 M | 203.4 M |
| EDIT | 2 M | 2 M | 2 M | 2 M | 10.6 M | 143.2 M | 185.3 M | 146.6 M | 134.8 M | 238.2 M | 139.7 M | 203.5 M | 141.5 M | 123.7 M | 146.9 M |
| CRSP | 945 K | 945 K | 945 K | 945 K | 945 K | 156 M | 315.5 M | 239.8 M | 456.6 M | 943.8 M | 1.2 B | 923 M | 211.9 M | 389.5 M | 528.6 M |
| RLAY | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 421.5 M | 42 M | 447.6 M | 958.1 M | 998.9 M | 143.7 M | 136.5 M |
| IPSC | 208 K | 208 K | 208 K | 208 K | 208 K | 208 K | 21.5 M | 44.1 M | 44.1 M | 44.1 M | 27.2 M | 56.4 M | 84.3 M | 47.3 M | 44.2 M |
| BPMC | 2 M | 2 M | 2 M | 2 M | 47.2 M | 162.7 M | 268.2 M | 673.4 M | 68.1 M | 113.9 M | 684.6 M | 209.9 M | 119.7 M | 71.3 M | 67.7 M |
Verve Therapeutics and related stocks such as Adaptive Biotechnologies, Beam Therapeutics, and Caribou Biosciences Cash description
Cash refers to the most liquid asset of Verve Therapeutics, which is listed under current asset account on Verve Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Verve Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Verve Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.My Equities
My Current Equities and Potential Positions
| Verve Therapeutics | VERV |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.6
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.